A recent study describes the success of using lenabasum, a cannabinoid receptor type 2 (CB2) agonist that triggers the resolution of inflammation, to treat amyopathic dermatomyositis. This phase 2 trial tested the potential benefits of activating the endocannabinoid system to reduce the inflammation causing the symptoms.